Global Patient Outcomes and Real-World Evidence, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Adv Ther. 2022 May;39(5):2052-2064. doi: 10.1007/s12325-022-02071-y. Epub 2022 Mar 14.
There is limited real-world evidence on the treatments for atopic dermatitis (AD) since dupilumab was approved in 2017. The objective of this study was to assess market share of drugs commonly prescribed for the treatment of AD and describe treatment patterns in patients diagnosed with AD.
This was a retrospective, observational study in adult patients with an ICD-10 diagnosis of AD between 2017 and 2019 using insurance claims data in the US population.
Market share cohorts consisted of 75,794 (2017) and 89,618 (2018) patients. Treatment patterns cohort had 68,588 patients with 63.56% female, mean (SD) age 43.54 (15.96) years, and mean (SD) Quan CCI 0.31 (0.85). Topicals had two-thirds market share by prescription volume (2017 = 65.56%; 2018 = 63.63%). Corticosteroids were the most prescribed topical (2017 = 71.94%; 2018 = 72.04%) and systemic (2017 = 30.59%; 2018 = 30.23%) drug class. Dupilumab had the highest medication adherence (proportion of days covered [PDC] ≥ 80%; 60.74%) and persistence (17.39%), lowest discontinuation rate (23.32%), and longest mean (SD) days on therapy 148.20 (101.77).
Topicals are the primary treatment for patients with AD, even though systemic users have higher medication adherence (PDC). Systemics provide a treatment alternative to topicals.
自 2017 年达必妥获批以来，针对特应性皮炎（AD）的治疗，实际证据有限。本研究旨在评估常用于 AD 治疗的药物的市场份额，并描述 AD 患者的治疗模式。
这是一项在美国人群中使用保险索赔数据进行的回顾性、观察性研究，纳入 2017 年至 2019 年期间 ICD-10 诊断为 AD 的成年患者。
市场份额队列包括 75794 例（2017 年）和 89618 例（2018 年）患者。治疗模式队列纳入 68588 例患者，其中 63.56%为女性，平均（标准差）年龄为 43.54（15.96）岁，平均（标准差） Quan CCI 为 0.31（0.85）。按处方量计算，局部用制剂占据了 2/3 的市场份额（2017 年=65.56%；2018 年=63.63%）。皮质类固醇是最常用的局部（2017 年=71.94%；2018 年=72.04%）和系统（2017 年=30.59%；2018 年=30.23%）药物类别。度普利尤单抗的药物依从性（覆盖天数比例[PDC]≥80%；60.74%）和持续性（17.39%）最高，停药率最低（23.32%），平均（标准差）治疗时间最长（148.20[101.77]天）。
尽管系统用药者的药物依从性（PDC）更高，但局部用制剂仍是 AD 患者的主要治疗选择。系统治疗为局部治疗提供了一种替代方案。
